Kentucky

Melanoma Clinical Trials- Recruiting

Phase
NCT00454701
Assessment and Tracking of Long-term Alefacept Safety		 Phase IV
NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery		 Phase III
NCT00297895
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)		 Phase III
NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery		 Phase III
NCT00553618
Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients		 Phase II
NCT01127451
Study of ONTAK in Patients With Stage IIIC and Stage IV Melanoma		 Phase II
NCT01136967
An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma		 Phase II
NCT01397708
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma		 Phase I
NCT01010984
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma		 Phase I
NCT01397708
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma		 Phase I
NCT01010984
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma		 Phase I
NCT00897442
Collecting Tumor Samples From Patients With Gynecological Tumors
NCT01260779
Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors
Updated from clinicaltrials.gov on 8/24/2011

Comments are closed.